Suppr超能文献

理解药效的时间过程:一种 PKPD 方法。

Understanding the time course of pharmacological effect: a PKPD approach.

机构信息

School of Pharmacy, University of Otago, PO Box 56, Dunedin, New Zealand.

出版信息

Br J Clin Pharmacol. 2011 Jun;71(6):815-23. doi: 10.1111/j.1365-2125.2011.03925.x.

Abstract

The key concepts that underpin the choice of drug and dosing regimen are an understanding of the drugs' effectiveness, the potential for adverse effects, and the expected time course over which both desired and adverse effects are likely to occur. Research in clinical pharmacology should therefore address three fundamental questions: (1) What is the magnitude of drug effects (beneficial or adverse) from a given dose? (2) How quickly will any given effects occur? (3) How long will these effects last? Under steady-state conditions, only the magnitude of drug effects can be examined. This requires researchers to consider non-steady-state conditions, which require more complex models and an understanding of the mechanisms that drive the time course of drug effect. The aim of this review is to provide a conceptual framework for understanding the time course of drug effects using pharmacokinetic-pharmacodynamic models. Key examples will illustrate how this can inform the optimal use of drugs in the clinic.

摘要

支撑药物选择和剂量方案选择的关键概念是对药物疗效、潜在不良反应以及预期的药物疗效和不良反应发生时间的理解。因此,临床药理学研究应该解决三个基本问题:(1)给定剂量的药物效应(有益或有害)的程度是多少?(2)任何给定的效果会多快发生?(3)这些效果会持续多久?在稳态条件下,只能检查药物效果的程度。这需要研究人员考虑非稳态条件,这需要更复杂的模型和对驱动药物效应时间过程的机制的理解。本综述的目的是提供一个使用药代动力学-药效动力学模型理解药物效应时间过程的概念框架。关键示例将说明如何为临床中药物的最佳使用提供信息。

相似文献

1
Understanding the time course of pharmacological effect: a PKPD approach.
Br J Clin Pharmacol. 2011 Jun;71(6):815-23. doi: 10.1111/j.1365-2125.2011.03925.x.
2
Understanding and applying pharmacometric modelling and simulation in clinical practice and research.
Br J Clin Pharmacol. 2017 Feb;83(2):247-254. doi: 10.1111/bcp.13119. Epub 2016 Sep 29.
3
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.
Br J Clin Pharmacol. 2011 Jun;71(6):807-14. doi: 10.1111/j.1365-2125.2010.03891.x.
4
Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
J Pharmacol Exp Ther. 2009 Dec;331(3):767-74. doi: 10.1124/jpet.109.157172. Epub 2009 Sep 24.
5
Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry.
Curr Top Med Chem. 2011;11(4):404-18. doi: 10.2174/156802611794480864.
6
The time course of drug effects.
Pharm Stat. 2009 Jul-Sep;8(3):176-85. doi: 10.1002/pst.393.
7
The integration of pharmacokinetics and pharmacodynamics: understanding dose-response.
Annu Rev Pharmacol Toxicol. 2004;44:111-36. doi: 10.1146/annurev.pharmtox.44.101802.121347.
8
Dosage regimen design: pharmacodynamic considerations.
J Clin Pharmacol. 1992 Jul;32(7):597-602. doi: 10.1002/j.1552-4604.1992.tb05766.x.
9
10
Optimising in vivo pharmacology studies--Practical PKPD considerations.
J Pharmacol Toxicol Methods. 2010 Mar-Apr;61(2):146-56. doi: 10.1016/j.vascn.2010.02.002. Epub 2010 Feb 11.

引用本文的文献

5
Safety and Efficacy of Zavegepant in Treating Migraine: A Systematic Review.
Cureus. 2023 Jul 17;15(7):e41991. doi: 10.7759/cureus.41991. eCollection 2023 Jul.
6
A Systematic Review on Antimicrobial Pharmacokinetic Differences between Asian and Non-Asian Adult Populations.
Antibiotics (Basel). 2023 Apr 23;12(5):803. doi: 10.3390/antibiotics12050803.
7
An individualized digital twin of a patient for transdermal fentanyl therapy for chronic pain management.
Drug Deliv Transl Res. 2023 Sep;13(9):2272-2285. doi: 10.1007/s13346-023-01305-y. Epub 2023 Mar 10.
8
Optimizing Clinical Outcomes Through Rational Dosing Strategies: Roles of Pharmacokinetic/Pharmacodynamic Modeling Tools.
Open Forum Infect Dis. 2022 Dec 16;9(12):ofac626. doi: 10.1093/ofid/ofac626. eCollection 2022 Dec.
9
Computational analysis of 5-fluorouracil anti-tumor activity in colon cancer using a mechanistic pharmacokinetic/pharmacodynamic model.
PLoS Comput Biol. 2022 Nov 17;18(11):e1010685. doi: 10.1371/journal.pcbi.1010685. eCollection 2022 Nov.

本文引用的文献

1
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.
Br J Clin Pharmacol. 2011 Jun;71(6):807-14. doi: 10.1111/j.1365-2125.2010.03891.x.
2
The 'apparent clearance' of free phenytoin in elderly vs. younger adults.
Br J Clin Pharmacol. 2010 Jul;70(1):132-8. doi: 10.1111/j.1365-2125.2010.03673.x.
3
The time course of drug effects.
Pharm Stat. 2009 Jul-Sep;8(3):176-85. doi: 10.1002/pst.393.
4
CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure.
Pharmacogenomics J. 2009 Jun;9(3):175-84. doi: 10.1038/tpj.2009.9. Epub 2009 Apr 14.
5
Heparin and low-molecular-weight heparin.
Thromb Haemost. 2008 May;99(5):807-18. doi: 10.1160/TH08-01-0032.
6
Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease.
Ther Drug Monit. 2007 Oct;29(5):619-25. doi: 10.1097/FTD.0b013e31811f39bb.
7
Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.
Clin Pharmacol Ther. 2007 Jul;82(1):3-6. doi: 10.1038/sj.clpt.6100248.
10
Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.
Annu Rev Pharmacol Toxicol. 2007;47:357-400. doi: 10.1146/annurev.pharmtox.47.120505.105154.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验